Atrial fibrillation

Thryv Therapeutics Inc. Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on:

Thursday, April 4, 2024

Atrial fibrillation, Medicine, LQTS, Metro Toronto Convention Centre, Conference, Heart failure, Biotechnology, Therapy

Montreal, Quebec--(Newsfile Corp. - April 4, 2024) - Thryv Therapeutics Inc., a Montreal based biotechnology company pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and heart failure, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Key Points:

Montreal, Quebec--(Newsfile Corp. - April 4, 2024) - Thryv Therapeutics Inc., a Montreal based biotechnology company pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and heart failure, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Irregular heartbeat can now be treated more safely and quicker than before

Retrieved on:

Monday, April 8, 2024

MBBS, Diabetes, Stroke, Atrial fibrillation, Risk, Patient, Apple Watch, Catheter, Collateral damage, Nebraska Medicine, Heart, Death, Medical device

"I started getting notifications that my heartbeat was fast and I wasn't really doing any activity," says the 63-year-old McCann.

Key Points:

"I started getting notifications that my heartbeat was fast and I wasn't really doing any activity," says the 63-year-old McCann.
“AFib is a very chaotic, disorganized, rapid heart rhythm,” says Payne.
“It usually involves the advancement of catheters into the heart and targeting tissue with some sort of thermal energy,” says Dr. Payne.
“They assured me that they did.”
Dr. Payne has now seen several patients for pulsed-field ablation since McCann and hopes to see even more.

Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market

Retrieved on:

Tuesday, April 2, 2024

Health, Coronary artery disease, Digital, GTG, Risk, Atrial fibrillation, Patient, Social media, ASX, Risk assessment, Breast cancer, Type

Digital strategies, such as GTG’s approach, are leveraging the growing awareness of the importance and utility of understanding a person’s individual risk of developing a range of diseases.

Key Points:

Digital strategies, such as GTG’s approach, are leveraging the growing awareness of the importance and utility of understanding a person’s individual risk of developing a range of diseases.
Know your risk and you and your doctor can take steps to diagnose disease early significantly improving health outcomes.
GTG predicts a significant surge in the adoption of risk assessment tests, driven by both patients and doctors.
The company sees its geneType digital strategy as spearheading a transformative shift from "sickcare" to genuine "healthcare".

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on:

Tuesday, April 9, 2024

Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points:

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
"Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."

Genomics plc and MassMutual's program enables more policyowners to understand health risks through innovative genetic testing

Retrieved on:

Tuesday, April 9, 2024

OXFORD, England and SPRINGFIELD, Mass., April 9, 2024 /PRNewswire/ -- Genomics plc (Genomics), a healthcare company transforming health through the power of genomics, and MassMutual, a leading mutual life insurance company in the United States, today announced the next phase of their innovative partnership enabling more eligible MassMutual policyowners to gain knowledge about their health in order to make informed, proactive decisions that may help them lead longer, healthier lives. The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases. The expansion follows a successful research collaboration in which more than 70% of policyowners who elected to use the risk assessment service reported intent to take preventative actions based on their risk scores, including plans to see their doctor or seek further screening.

Key Points:

The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases.
Genomics' at-home test studies millions of small variations in DNA, generating polygenic risk scores, that can inform the likelihood of certain conditions.
During the initial Genomics and MassMutual research collaboration, 1 in 5 policyowners learned that they are at a higher risk for preventable diseases.
MassMutual only receives high-level, anonymized data from Genomics that allows the company to better understand aggregate policyowners' health and behaviors and interest in these types of offerings.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on:

Tuesday, April 9, 2024

Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points:

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
"Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."

The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation

Retrieved on:

Monday, April 8, 2024

Freedom, Atrial fibrillation, Risk, Patient, Stroke, PFA, Medtronic, Femoral vein, Pulse, Heart failure, Ventricular fibrillation, MPH, Index, Heart, Safety, AAD, Annual general meeting, Cardiac tamponade, Pulmonary vein stenosis

DUBLIN and BERLIN, April 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib). Interim findings from the first-in-human Sphere-360 study were presented as a late-breaking clinical trial at the European Heart Rhythm Association (EHRA) 2024 Annual Meeting.

Key Points:

Interim findings from the first-in-human Sphere-360 study were presented as a late-breaking clinical trial at the European Heart Rhythm Association (EHRA) 2024 Annual Meeting.
The Sphere-360 catheter was developed with the goal to simplify the atrial fibrillation procedure while enhancing efficiency and providing high durability of lesions.
Furthermore, the catheter is fully integrated with the Affera™ Mapping and Ablation System for complete visualization inside the heart and electroanatomical mapping, making it a true all-in-one single-shot catheter for mapping, ablation, and validation.
"These results are very encouraging as they show the Sphere-360 catheter has the potential to be an important part of next generation AFib care."

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Retrieved on:

Thursday, March 21, 2024

MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update.

Key Points:

- FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid-2024
MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update.
There was no revenue recorded for the fourth quarter of 2023, compared with $3.5 million the fourth quarter of 2022.
Commercial expense for the fourth quarter of 2023 was $5.0 million, compared with $2.6 million for the prior year period.
For the fourth quarter of 2023, net loss was $13.6 million, compared to $13.2 million for the prior year period.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on:

Friday, March 15, 2024

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points:

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

MarinHealth Medical Center Becomes First Hospital in Northern California to Successfully Implant AVEIR™ DR, the World’s First Dual Chamber Leadless Pacemaker System

Retrieved on:

Friday, April 5, 2024

MarinHealth Medical Center today announced the successful implantation of an AVEIR™ DR pacemaker system, becoming the first hospital in Northern California to insert the world’s first dual chamber leadless pacemaker system.

Key Points:

MarinHealth Medical Center today announced the successful implantation of an AVEIR™ DR pacemaker system, becoming the first hospital in Northern California to insert the world’s first dual chamber leadless pacemaker system.
“MarinHealth is proud to be at the forefront in the clinical care of heart rhythm disorders.
Now, we are excited to become the first center in Northern California to offer dual chamber leadless pacemaker technology, which provides yet another state-of-the-art solution for heart rhythm patients in our community,” said Anita Chandrasena, MD , Chief Medical Officer of MarinHealth.
Roughly one-tenth the size of a traditional pacemaker, the dual chamber AVEIR leadless pacing system is made up of two devices: a ventricular (VR) and an atrial (AR) leadless pacemaker.